Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations (NASDAQ:CELC)

Celcuity (CELC) Q4 2025 earnings call: gedatolisib NDA priority review, VIKTORIA-1 data and launch plans ahead of July 2026 PDUFA—read now.

You are being redirected to the original discussion. Please continue if you want to read the full post.

You will be redirected in 3 seconds.